home / stock / nrx:cc / nrx:cc news

NRX:CC News and Press, NurExone Biologic Inc. From 04/25/24

Stock Information
Company Name: NurExone Biologic Inc.
Stock Symbol: NRX:CC
Market: TSXVC
Website: nurexone.com
Menu
NRX:CC NRX:CC Quote NRX:CC Short NRX:CC News NRX:CC Articles NRX:CC Message Board
Get NRX:CC Alerts

News, Short Squeeze, Breakout and More Instantly...
NRX:CC - Shares of Biopharma Up After News of Uplisting

2024-04-25 10:51:54 ET When firms uplist to a higher exchange, they gain visibility and greater access to investors. And today, news of a strategic expansion in the United States is sending shares of this biopharma company up this morning despite a generally down-trending mood on the Street...
NRX:CC - NurExone Biologic Inc. Announces Strategic Expansion to US Financial Markets with Approval of OTCQB Listing Application and DTC Eligibility

TORONTO and HAIFA, Israel, April 25, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “ Company ” or “ NurExone ”), a pioneering biopharmaceutical company is pleased to announce that its common shares are now quoted for trading on...

NRX:CC - NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at European Conference on Exosomes and Regenerative Medicine

TORONTO and HAIFA, Israel, April 19, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, is pleased to announce that Dr. Lior Shaltiel, CEO and Director at NurExone, was invit...

NRX:CC - NurExone Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Company Update

TORONTO and HAIFA, Israel, April 02, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, developing regenerative medicine therapies, today provided a business update and repor...
NRX:CC - Gross Proceeds Close of $4M CAD Generated for NurExone From Warrants Exercise

TORONTO and HAIFA, Israel, March 27, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), is pleased to announce that, the Company completed a combined exercise and expiration of 12,682,340 common share purchase warr...

NRX:CC - In Preparation for Expected Human Clinical Trials, NurExone Signs Agreement for Large Scale Preclinical Testing for Its Spinal Cord Injury Therapy, ExoPTEN

TORONTO and HAIFA, Israel, March 22, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “ Company ” or “ NurExone ”), a pioneering biopharmaceutical company, developing regenerative medicine therapies, is proud to announce a strateg...

NRX:CC - NurExone's Strategic Update: Submission of OTCQB Listing Application to Initiate US financial presence

TORONTO and HAIFA, Israel, March 15, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “ Company ” or “ NurExone ”), a pioneering biopharmaceutical company, developing regenerative medicine therapies, announces today its intention ...
NRX:CC - NurExone establishing State-of-the-Art Research and Development Facility in Haifa, Israel

TORONTO and HAIFA, Israel, March 08, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “ Company ” or “ NurExone ”), a pioneering biopharmaceutical company, finalized today a lease and constructing agreement for nearly 200 square m...

NRX:CC - NurExone Presenting Novel Regulatory Pathways for Exosomes Therapies at Global Summit

TORONTO and HAIFA, Israel, March 01, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, is pleased to announce that Dr. Ina Sarel, the Head of CMC, Quality and Regulatory Aff...

NRX:CC - NurExone's Intellectual Property Portfolio Expands

TORONTO and HAIFA, Israel, Feb. 20, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, proudly underscores its expanding Intellectual Property (IP) portfolio, which will serv...
Previous 10 Next 10